A trial aimed at protecting muscle
iBio announced regulatory and ethics approvals in Australia to start a first‑in‑human Phase 1 trial of IBIO‑600, an anti‑myostatin antibody designed for overweight and obese patients — a therapy aimed at preserving or increasing muscle while addressing weight. (The company confirmed the go‑ahead on April 8, marking a clinical push to pair fat loss strategies with muscle‑sparing biology.) (tipranks.com)
Weight-loss drugs can shrink more than fat. A 2025 Nature study said up to 40% of the weight lost with glucagon-like peptide-1 medicines can come from lean mass, which includes muscle. (nature.com) Muscle matters because it is the body’s engine. It helps people climb stairs, keeps blood sugar under control, and burns more energy at rest than fat tissue does. (academic.oup.com) One protein helps set the body’s muscle limit. That protein is myostatin, and researchers often describe it as a brake that tells skeletal muscle not to keep growing. (ibioinc.com) An antibody is a lab-made protein built to stick to one target, like a key cut for one lock. iBio’s drug candidate IBIO-600 is an antibody designed to block myostatin so that brake is loosened. (ibioinc.com) That is the setup behind the news from April 8, 2026. iBio said Australian regulators and a Human Research Ethics Committee cleared the company to begin its first human trial of IBIO-600 in overweight and obese adults. (ibioinc.com) The study is a Phase 1 trial, which means the first job is basic safety. iBio said the trial is randomized, double-blind, placebo-controlled, and single ascending dose, so small groups will receive rising dose levels while researchers watch for side effects and measure how the drug moves through the body. (ibioinc.com) Australia is often used for early human studies because companies can move from ethics and regulatory clearance into dosing on a relatively fast timetable. iBio said it expects the first participant to be dosed in the second quarter of 2026. (ibioinc.com) iBio is also trying to make this antibody last a long time in the bloodstream. The company said monkey data presented in 2025 suggested a possible human half-life of as long as 130 days, which is why it talks about dosing as infrequently as two to four times a year. (ibioinc.com 1) (ibioinc.com 2) This is not a proven muscle-saving treatment yet. It is a first-in-human test, and many drugs that look promising in animals never make it through human trials. (ibioinc.com) But the direction is clear. Drug developers are now chasing “better weight loss,” not just lower body weight, and that means trying to cut fat without giving up the muscle people need to stay strong after the pounds come off. (academic.oup.com)
